MarketInOut Stock Screener Log In | Sign Up
 

CG Oncology Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 08/21/2026
CG Oncology Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,890.9 mln
Float64.73 mln
Earnings Date11/12/2026

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

1.04
Highly suspicious

1-Year Forecast

91.08
Modest upside

Relative Strength

84 / 100
Strongly outperforming

Debt / Equity

0.01
Debt-free

ROE

-26.51
Deeply negative

Business Description

CG Oncology is a clinical-stage biopharmaceutical company based in Irvine, California, focused on developing a single investigational treatment called cretostimogene grenadenorepvec for people with bladder cancer. The therapy works by stimulating the immune system and is currently being tested across multiple advanced clinical trials targeting various forms of non-muscle-invasive bladder cancer, including cases where standard BCG treatment has not worked. Founded in 2010 and formerly known as Cold Genesys Inc., the company is working to establish cretostimogene as both a standalone treatment and a potential option for patients at different stages and risk levels of the disease.

Key Fundamentals

EPS-2.69
ROE-26.51
RPS0.08
ROIC-628
ROA-25.25
EBITDA, mln-250
EV / EBITDA-26.35
EV / EBIT-26.07
Revenue, mln6.23
EV / Revenue1,105

Financial Strength

Altman Z-Score91.12
Piotroski F-Score 3 / 9
Beneish M-Score1.04
1-Year Target Price91.08
Short Ratio12.31
Short % of Float13.65

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.37% 89 / 100   
1 Month 12.22% 82 / 100   
2 Months 14.77% 83 / 100   
6 Months 38.49% 90 / 100   
1 Year 213% 97 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us